Exelixis 10-Q: Q3 Revenue $658.7M, EPS $0.85, $1.4B Cash, Handa Generic Approved
EXEL sits 84% above its 52-week low of $36.
Summary
Exelixis' Q3 10-Q confirms $658.7M of revenue and $0.85 diluted EPS with $1.4B in cash after heavy buybacks, and discloses that Handa's generic cabozantinib capsules received full FDA approval in September 2026.
Key Events · Earnings and Guidance · EXEL
-
Q3 Revenue Up 10% to $658.7M
Total revenues were $658.7 million versus $597.8 million a year earlier, with net product revenues of $604.9 million versus $542.9 million; GAAP diluted EPS was $0.85 versus $0.69.
-
Cash Falls to $1.4B After Buybacks
Cash, cash equivalents and marketable securities were $1.4 billion at September 30, 2026 versus $1.7 billion at December 31, 2025, after $1,003.3 million of share repurchases in the first nine months; $347.9 million remains under the May 2026 program.
-
Handa Generic Wins Full FDA Approval
On September 3, 2026 the FDA denied Exelixis' citizen petition and granted full approval to Handa's 505(b)(2) NDA for cabozantinib capsules; the company says it continues to evaluate legal and strategic options.
-
MSN Patent Trial Set for November
The '039 Patent litigation with MSN is scheduled for trial on November 2, 2026, and MSN has until October 30, 2026 to seek CAFC rehearing; the Azurity settlement licenses its product from December 1, 2030.
Analysis · EXEL · Life Sciences
The 10-Q confirms the quarter the 8-K previewed and fills in the balance sheet: revenue rose 10% to $658.7M and diluted EPS reached $0.85, while cash, equivalents and marketable securities fell to $1.4B from $1.7B at year-end after $1.0B of buybacks. The bigger read-through is on the cabozantinib franchise. Handa's 505(b)(2) version of cabozantinib capsules won full FDA approval on September 3, 2026 after the company's citizen petition was denied, and the Azurity settlement only pushes that entrant to December 1, 2030. With MSN's '039 Patent trial set for November 2, 2026 and a rehearing deadline of October 30, 2026, the patent wall protecting the drug that drives nearly all revenue is the thing that matters here, not the quarter itself.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EXEL was trading at $66.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4B. The 52-week trading range was $36.00 to $67.52. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.